Table 3 Common treatment related adverse events
Dose level | ||||
|---|---|---|---|---|
1 ( n =7) | 2 ( n =7) | 3 ( n =6) | ||
Drug-related AE (%) | Grade | Cediranib 20 mg RO4929097 10 mg | Cediranib 20 mg RO4929097 20 mg | Cediranib 30 mg RO4929097 20 mg |
Diarrhoea | All 3–4 | 6 (86%) 0 (0%) | 3 (43%) 0 (0%) | 4 (66%) 0 (0%) |
Hypertension | All 3–4 | 6 (86%) 2 (28%) | 2 (28%) 0 (0%) | 4 (66%) 1 (17%) |
Fatigue | All 3–4 | 3 (43%) 0 (0%) | 3 (43%) 0 (0%) | 4 (66%) 0 (0%) |
Nausea | All 3–4 | 3 (43%) 0 (0%) | 4 (57%) 0 (0%) | 4 (66%) 0 (0%) |
Hypothyroidism | All 3–4 | 3 (43%) 0 (0%) | 2 (28%) 0 (0%) | 3 (50%) 0 (0%) |
Headache | All 3–4 | 4 (57%) 0 (0%) | 1 (14%) 0 (0%) | 3 (66%) 0 (0%) |
Hypophosphatemia | All 3–4 | 3 (43%) 1 (14%) | 2 (28%) 0 (0%) | 2 (33%) 0 (0%) |
Increased ALT | All 3–4 | 2 (28%) 0 (0%) | 3 (43%) 1 (14%) | 3 (50%) 0 (0%) |
Increased AST | All 3–4 | 0 (33%) 0 (0%) | 5 (71%) 1 (14%) | 2 (33%) 0 (0%) |
